Christian Hansen : Q3 Investor presentation 2022/23

Chr. Hansen Q3 2022/23

Investor presentation July 6, 2023

Safe harbor statement

This presentation contains forward-looking statements that reflect management's current views and expectations with respect to Chr. Hansen's future and potential financial performance.

Those forward-looking statements are based upon data and information currently available to the company, and on a variety of assumptions, many of which may be beyond our control and subject to risks and uncertainties that may cause the actual results of the Company or the industry to differ materially from such forward-looking statements.

The information, opinions and forward-looking statements are provided as of the date stated in this document and the Company is under no obligation to publish any updates thereof except for what is required by applicable law or stock exchange rules and regulations.

Solid third quarter proves the strength of the organization

Financial highlights Q3/YTD 2022/23

ORGANIC REVENUE GROWTH

9%

YTD 2022/23: 10%

EBIT MARGIN

before special items

27.5% (0.8%-pt vs. LY)

YTD 2022/23: 26.4%

(0.1%-pt vs. LY)

FREE CASH FLOW

before acquisitions and special items

EUR 76m

YTD 2022/23: EUR 133m

3

Solid result driven by continued growth in lighthouses and stable core

Strategic and operational highlights Q3/YTD 2022/23

2025 STRATEGY

REINVEST		REINVEST
Demand focused on productivity		New customer and application center
improvement and sustainability		for meat and prepared foods
impact in FC&E			inaugurated to strengthen customer
			collaboration in fermented meat
			products

LEVERAGE	GROUP
EU approval of final HMO in Chr.	Increased contribution from
Hansen's 5HMO mix product for	inflation-drivenprice increases
highest use levels in infant formula

ORGANIC GROWTH

Q3/YTD 2022/23
		19%
	15%
9%			9%	10%
8%
Core 1	Lighthouses 1	Group
Q3 22/23	YTD 22/23

1 Core includes FC&E ex. Bioprotection and Fermented Plant Bases, Human Health and Animal Health. Lighthouses includes Bioprotection, Fermented Plant Bases, HMO and Plant Health.

4

Continued strong growth in FC&E and solid growth in H&N driven by price

Organic sales performance by business area

GROUP1

											9%
4%	6%	9%	14%	9%	6%	10%	11%
	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2	Q3
	20/21			21/22				22/23

FOOD CULTURES & ENZYMES

HEALTH & NUTRITION2

											10%												7%
5%	10%	7%	7%	6%	5%	8%	12%		0%		13%	26%	13%	6%	12%	9%
														-4%
	Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2	Q3		Q3	Q4		Q1	Q2	Q3	Q4		Q1	Q2	Q3
	20/21			21/22				22/23			20/21			21/22				22/23

	VOLUME/	PRICE	FX	EUR
	MIX			GROWTH
Q3	+2%	+7%	-4%	+5%
YTD	+4%	+6%	0%	+10%

	VOLUME/	PRICE	FX	EUR
	MIX			GROWTH
Q3	+1%	+9%	-5%	+5%
YTD	+2%	+8%	0%	+10%

	VOLUME/	PRICE	FX	EUR
	MIX			GROWTH
Q3	+2%	+5%	-1%	+6%
YTD	+6%	+3%	+2%	+11%

1. Historic figures (20/21) refer to continuing operations (i.e., excluding Natural Colors).
2. The acquisition of HSO HC is included in organic growth since Q3 2020/21 (closing April 2020), UAS Labs (closing July 2020) and Jennewein (closing October 2021) since Q1 2021/22.

5